Related Experiment Video

Updated: May 16, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Yttrium 90 radioembolization: the horizon is changing for patients with intermediate and advanced hepatocellular

Luigi Bolondi, Fabio Piscaglia

    Hepatology (Baltimore, Md.)
    |November 24, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
    05:31

    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

    Published on: September 20, 2020

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
    09:49

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

    Published on: December 2, 2013

    Related Experiment Videos

    Last Updated: May 16, 2026

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
    09:11

    Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

    Published on: May 24, 2024

    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
    05:31

    Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

    Published on: September 20, 2020

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
    09:49

    Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

    Published on: December 2, 2013

    Related Concept Videos

    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against specific...

    Articles linked to this work by shared authors, journal, and citation graph.

    Lenvatinib versus Sorafenib in First-Line Treatment of Older Patients with Unresectable Hepatocellular Carcinoma: A Subgroup Analysis of the REFLECT Trial.

    Liver cancer·2026

    Use of Next-Generation Sequencing and Whole-Exome Sequencing in the Diagnosis of Adult-Onset Familial Intrahepatic Cholestasis: Challenges in Interpreting Variants of Uncertain Significance.

    Diagnostics (Basel, Switzerland)·2026

    Parvovirus B19 infection as a trigger of acute cholestasis in heterozygous genetic BSEP deficiency: a case report and review of the literature of acute parvovirus B19-related hepatitis.

    Internal and emergency medicine·2026

    Somatic pathogenic mitochondrial DNA mutations independently predict worse prognosis in hepatocellular carcinoma.

    Scientific reports·2026

    Viscoelastic Tests in Cirrhotic Patients Undergoing Invasive Procedures: A Systematic Review and Meta-Analysis of RCTs.

    Liver international : official journal of the International Association for the Study of the Liver·2026

    Validation of a pan-ELastography Machine-learning (ELM) score to predict clinically significant portal hypertension in compensated advanced chronic liver disease.

    Journal of hepatology·2026

    The hepatic sinusoid as a regulatory niche: From cellular specialization to precision hepatology.

    Hepatology (Baltimore, Md.)·2026

    Safety and efficacy of zetomipzomib in relapsed or insufficiently responding autoimmune hepatitis: Results from the randomized, double-blind, placebo-controlled, phase 2a PORTOLA study and open-label extension.

    Hepatology (Baltimore, Md.)·2026

    Hepatitis B virus proteome analysis identifies apolipoprotein C1 facilitating particle production and virus entry.

    Hepatology (Baltimore, Md.)·2026

    Lactulose with or without TeleTai-Chi for the prevention of falls: A sequential multiple assignment randomized controlled trial (LiveSMART).

    Hepatology (Baltimore, Md.)·2026

    VPS13D protects against alcohol-associated steatohepatitis by regulating organelle contacts and VLDL secretion.

    Hepatology (Baltimore, Md.)·2026

    Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH.

    Hepatology (Baltimore, Md.)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us